-
A Deep Dive Into MannKind's Big Bet On Afrezza
Wednesday, October 11, 2017 - 11:45am | 1256Read More...It’s been a long road for MannKind Corporation (NASDAQ: MNKD) and its Afrezza inhalable insulin product. However, a generous new FDA label this week may be the light at the end of the tunnel. Here’s a look at inhalable insulin’s long journey and what the new FDA ruling means for...
-
New Label For Afrezza Could Turn Things Around At MannKind
Tuesday, October 10, 2017 - 10:21am | 438Read More...Despite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of...
-
What A Week For MannKind
Friday, October 6, 2017 - 1:21pm | 430Read More...MannKind Corporation (NASDAQ: MNKD) investors haven’t had much to cheer about lately, with the stock down more than 80 percent in the past three years. However, this week provided investors with a bit of optimism and traders with a huge opportunity for profits. What Happened? MannKind...
-
MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says
Tuesday, August 30, 2016 - 3:50pm | 310Read More...Biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) is "making progress" in developing a less costly alternative to Mylan NV (NASDAQ: MYL)'s EpiPen. According to Connecticut-based News Times, MannKind's local manufacturing facility employs around 150 people in the city and plays a key...
-
Why Goldman Is Still Selling Mannkind
Wednesday, March 30, 2016 - 2:53pm | 243Read More...Goldman Sachs maintained its Sell rating on MannKind Corporation (NASDAQ: MNKD) as it believes the recent rally in shares is not related to fundamentals as news flow is negative since Sanofi SA (ADR) (NYSE: SNY) dropped out of the Afrezza partnership in January. "Specifically, Afrezza is...
-
MannKind Is Plummeting
Tuesday, January 5, 2016 - 10:19am | 172Read More...Shares of MannKind Corporation (NASDAQ: MNKD) plummeted more than 40 percent Tuesday morning after the company announced the termination of its licence and collaboration agreement with Sanofi SA (ADR) (NYSE: SNY). The prior agreement consisted of the development and commercialization of Afrezza...
-
Is MannKind Becoming A Penny Stock? Vetr Crowd Isn't Optimistic
Monday, December 7, 2015 - 3:23pm | 288Read More...A couple of months ago, the Vetr crowd issued a 5 star rating on shares of MannKind Corporation (NASDAQ: MNKD). Since then, the stock price has fallen about 40 percent from above $3.10 to under $1.90. Now, the Vetr crowd has decided to downgrade the company to 1 star. Broadly speaking...
-
Diabetic Investor On MannKind: 'There's A Reason Why So Many People Are Short This Stock'
Tuesday, September 29, 2015 - 3:11pm | 381Read More...On Tuesday, Benzinga spoke with Diabetic Investor David Kliff about MannKind Corporation (NASDAQ: MNKD), after he said in a tweet “Thinking $MNKD and #afrezza are going to turnaround is like believing the Chicago Bears are going to the Superbowl this year.” Speaking on Afrezza:...
-
Calls Of Note: The Research Moving Stocks Today
Thursday, August 6, 2015 - 12:03pm | 907Read More...The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." FBR: Upgrading Sprint David Dixon of FBR & Co. upgraded shares of Sprint Corp (NYSE: S) to Outperform from Market Perform with...
-
MannKind Corporation Sinks: CFO Says 'We're Not There Yet' With Afrezza
Wednesday, June 10, 2015 - 4:30pm | 430Read More...MannKind Corporation (NASDAQ: MNKD) fell more than 7 percent after the company acknowledged it hasn't hit the break-even point for its inhaled insulin product Afrezza. "These low volumes make it painful because the margins aren't there," Chief Financial Officer Matthew J. Pfeffer said at a Goldman...
-
Jefferies: MannKind's Consumer Ads For Afrezza May Increase Awareness
Thursday, June 4, 2015 - 1:36pm | 343Read More...MannKind Corporation (NASDAQ: MNKD)'s plans for direct-to-consumer advertising for its Afrezza inhaled insulin product may gradually increase awareness of the product, an analyst said Thursday. The biopharma company recently traded at $5.93, up about 7 percent. Early sales of Afrezza have...
-
MannKind 'Facing Low Profitability And Delayed Profits' As Afrezza Ramp Fizzles, Goldman Says
Monday, May 11, 2015 - 3:35pm | 264Read More...MannKind Corporation (NASDAQ: MNKD) shares fell 5 percent Monday after JP Morgan downgraded the stock from Neutral to Underweight. The demotion followed last Friday’s earnings release, which disappointed many investors and analysts. Jefferies analyst Shaunak Deepak maintained a Buy rating...
-
Piper Jaffray Dishes On MannKind's Afrezza Data
Monday, May 11, 2015 - 11:52am | 601Read More...MannKind Corporation (NASDAQ: MNKD) reported first quarter 2015 results on May 7, revealing underwhelming sales and a mediocre Afrezza launch. Shares of MannKind last closed at $4.02, just above the 52-week low of $3.52. Some analysts are beginning to doubt if the company can make a comeback....
-
MannKind Disappoints Again With Afrezza Sales
Thursday, April 30, 2015 - 1:40pm | 208Read More...Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. MannKind Corporation (NASDAQ: MNKD) shares were trading lower by $0.24 (5.2 percent) at $4.34 in Thursday's session. The price of the issue continues to decline as sales for its main drug,...
-
What's Afrezza's Ultimate Potential For MannKind?
Thursday, April 16, 2015 - 11:39am | 251Read More...In a report published Thursday, RBC Capital Markets analyst Adnan Butt commented that MannKind Corporation (NASDAQ: MNKD) has seen its Afrezza slow to take off and first quarter sales are likely to miss consensus estimates. Butt noted that the consensus estimate for MannKind is approximately $3.9...
